Swipe Left For English News
上海,
2024年4月2日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司荣获2024年“CDMO领军企业奖”，在综合、大型药企、新兴药企三个组别的评选中，包揽包括能力（Capabilities）、兼容性（Compatibility）、专业性（Expertise）、质量（Quality）、可靠性（Reliability）和服务（Service）在内的全部六大核心单项奖。特别值得一提的是，在新兴药企组的兼容性（Compatibility）和服务（Service）类别评选中，药明生物以卓越表现荣膺“冠军”称号。
2023年，公司成功支持全球客户完成110个新药临床试验申请（IND）。公司已累计通过超1200次全球客户质量审计，并通过美国FDA、欧盟EMA、中国NMPA 等权威药品监管机构的33次检查。原液和生物制剂生产的工艺验证（PPQ）成功率达 97% 以上，充分展现其一如既往的卓越质量水平。
这是药明生物连续第7年斩获“CDMO领军企业奖”。药明生物凭借全球领先的生物药发现、开发和生产的一体化服务平台赋能全球客户，以可靠的专业能力及创新技术，提供兼具时间和成本效益的解决方案，赋能客户的生物药及疫苗产品实现从概念到商业化生产，造福全球病患。
陈智胜博士
首席执行官
药明生物
我们很荣幸能够在2024年‘CDMO领军企业奖’的各项评选中，获得制药企业的一致认可与信赖。这一非凡成绩印证了公司全球员工的卓越执行力。未来，我们将继续为全球合作伙伴提供高质高效的CRDMO服务，助力其创新疗法研发，并推进至临床和商业化上市，惠及全球广大病患。
“CDMO领军企业奖”由专业媒体Outsourced Pharma和Life Science Leader共同颁发，旨在表彰全球优秀的研发生产服务企业。本年度该奖项围绕23个关键指标，由近18个月内使用过CDMO服务的制药企业和生物制药企业，为其CDMO合作伙伴进行评价。根据权威第三方机构确定，全球总计72家CDMO公司参评。
推荐阅读
新闻速递 | 前沿洞见 | 精彩活动
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年12月底，药明生物帮助客户研发和生产的综合项目高达698个，其中包括24个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
业务垂询
info@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Wins 2024 CDMO Leadership Awards
in All Categories
Shanghai,
April 2, 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it was a winner of the 2024 CDMO Leadership Awards in all six categories – Capabilities, Compatibility, Expertise, Quality, Reliability, and Service – across all three groups of Big Pharma, Small Pharma and Overall. In addition, the company was named a "Champion" for its particularly high ratings in the categories of Compatibility and Service for the Small Pharma group.
This is the seventh consecutive year the CDMO Leadership Awards have recognized WuXi Biologics. The company has established collaborations with global clients, providing them with expertise, leading technologies and biologics research, development and manufacturing services to quickly and cost-effectively advance biologics and vaccines from concept to commercial manufacturing.
In the past year alone, WuXi Biologics has facilitated 110 IND fillings. To date, the company has passed over 1,200 client quality audits, completed 33 regulatory inspections conducted by the U.S. FDA, EU EMA, China NMPA and other global regulatory agencies, and maintained PPQ success of 97%+ for drug substance and drug product manufacturing, demonstrating a proven track record of premier quality.
Dr. Chris Chen
Chief Executive Officer
WuXi Biologics
We are honored to have been recognized by pharma companies across all the CDMO Leadership Awards benchmark categories. This is a testament to the extraordinary performance of our highly dedicated staff worldwide and the trustworthiness we have earned enabling our clients to efficiently advance their breakthrough treatments to market and ultimately benefit patients.
The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Leader. For the 2024 awards, 72 contract manufacturing organizations – identified based on authoritative third-party research – were evaluated on more than 23 different performance metrics by pharma and biopharma companies who have utilized these outsourcing services within the past 18 months.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Business
Info@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
